Voyager Awarded Cancer Research Mission Management Contract

The contract covers hardware adaptation, orbital experiment operations and the return of samples and data after the study.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Mission tests an implant designed to train immune cells to attack tumors

DENVER--(BUSINESS WIRE)-- Voyager Technologies (NYSE: VOYG) signed a contract with the Center for the Advancement of Science in Space to manage Symphony Biosciences’ biopolymer cancer implant experiment aboard the International Space Station (ISS). The contract underscores the continued demand for access to low-Earth orbit for biopharmaceutical research.

“Our mission management service exists to clear the obstacles between breakthrough research and low-Earth orbit,” said Scott Rodriguez, vice president, Government Programs, Voyager. “Microgravity provides a cancer research environment where tumor cells form complex, three-dimensional structures that are obscured in Earth cultures, and our role is to make sure nothing stands between companies like Symphony Biosciences and unlocking better ways to fight cancer and improve life on Earth.”

Under the contract, Voyager will adapt Symphony Biosciences’ sample hardware to station equipment, ensure the clearing of NASA safety reviews and manage integration and stowage for launch. From the Voyager mission operations room, mission managers will oversee on-orbit operations like incubation and fluorescence reading, including assisting astronauts in running the experiment. When the study concludes, Voyager will return all samples and data, as well as provide post-flight and close-out reporting.

The research focuses on testing SymphNode, a device designed to restore the body’s immune response under immunosuppressive conditions, recruiting and activating a patient’s T cells to fight their cancer. The study aboard the ISS is looking to replicate the in vitro studies done on Earth with human T cells and tumor cells to assess the efficacy of immune cells that were trained in SymphNode.

Voyager has two decades of flight heritage across more than 1,400 missions and is prepared to seamlessly bridge operations from the ISS to next-generation commercial platforms, including Starlab.

About Voyager Technologies

Voyager Technologies is a defense technology and space solutions company that enables mission-ready systems that secure today and power what’s next for the U.S. and partner nations. From propulsion and energetics to advanced electronics, mission management and space exploration, Voyager delivers capabilities that protect national security, reinforce the industrial base and expand human presence beyond Earth. For more information visit: voyagertechnologies.com and follow on LinkedIn and X.

Cautionary Statement Concerning Forward-Looking Statements:

This press release contains “forward-looking statements.” All statements, other than statements of historical fact, including those with respect to Voyager Technologies, Inc.’s (the “Company’s”) mission statement and growth strategy, are “forward-looking statements.” Although the Company’s management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve many risks and uncertainties, which could cause the Company’s future results to differ materially from those anticipated. Potential risks and uncertainties include, among others, the Company’s ability to sustain and generate growth, ability to generate a sustainable order rate for its products and services and develop new technologies to meet customer needs, general economic conditions and conditions affecting the industries in which the Company operates; the uncertainty of regulatory requirements and approvals; and the ability to obtain necessary financing on acceptable terms or at all. Readers should not place any undue reliance on forward-looking statements since they involve these known and unknown uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261005453631/en/

Media Contact
Nora Ellish, media@voyagertechnologies.com

Source: Voyager Technologies

Key Terms

biopolymer technical

A large molecule made of repeating smaller units that is produced by living organisms or derived from biological sources; examples include proteins, polysaccharides (like cellulose), and nucleic acids, as well as polymers chemically synthesized from renewable biological feedstocks. Structurally it is like beads on a string: many repeating subunits joined into long chains or networks. In commercial and regulatory contexts the term highlights origin and often implies properties such as biocompatibility or biodegradability, but not every biopolymer is readily biodegradable and the specific material properties depend on its chemistry and processing.

in vitro medical

In vitro describes laboratory tests performed on cells, tissues, or biological molecules outside a living body—literally “in glass,” such as in test tubes or dishes. For investors, in vitro results are an early sign that a drug or technology has a desired effect under controlled conditions, but they don’t guarantee it will work or be safe in animals or people; think of them as a prototype tested on a bench rather than in real-world use.

immunosuppressive conditions medical

Health states or diagnoses that weaken or impair the immune system’s ability to detect and fight infections and abnormal cells; they include congenital immune deficiencies, chronic diseases that damage immune function (for example advanced HIV/AIDS), and conditions produced by medical treatments such as chemotherapy, radiation, corticosteroids, certain biologic agents, or other immunosuppressive drugs. Because the immune response is reduced, people with immunosuppressive conditions are more susceptible to infections and often have diminished responses to vaccines or immune-based therapies, and clinicians assess these conditions by medical history, clinical tests, and current medication regimens.

fluorescence reading technical

A fluorescence reading is a numeric measurement of light emitted by a fluorescent dye or label in a laboratory sample after the dye has been excited by a specific wavelength; the intensity of that emitted light is used as a proxy for the amount or activity of a target substance in the sample. It is produced by instruments (fluorometers, plate readers, qPCR machines) and can be influenced by factors such as background signal, quenching, instrument settings and photobleaching, so readings typically require controls and calibration to be interpreted reliably.